AUCTORES
Globalize your Research
Case Report | DOI: https://doi.org/10.31579/2690-4861/352
1 Pulmonology Service, La Princesa Research Institute (IIS Princesa), La Princesa University Hospital, Madrid, Spain.
2 Department of Medicine. Autonomous University of Madrid, Madrid, Spain.
3 Virology Unit, PharmaMar, SA, Madrid, Spain.
*Corresponding Author: Pedro Landete, Pulmonology Service, La Princesa Research Institute (IIS Princesa), La Princesa University Hospital, Madrid, Spain.
Citation: Landete P., Valenzuela C., Hevia M., Lloris R., María P. Pire, et al., (2023), SARS-CoV-2-Related Persistent Pulmonary Affection Case in A 55-Year-Old Gastric MALT Lymphoma Patient on Rituximab, International Journal of Clinical Case Reports and Reviews, 15(2); DOI:10.31579/2690-4861/352
Copyright: © 2023, Pedro Landete. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 14 November 2023 | Accepted: 29 November 2023 | Published: 05 December 2023
Keywords: plitidepsin; COVID-19; immunocompromised patients; MALT lymphoma; persistent viral SARS-CoV-2 replication; SARS-CoV-2
Following a mild symptomatic SARS-CoV-2 infection, a 55-year-old patient with gastric MALT lymphoma, currently treated with rituximab, experienced persistent symptoms. Over subsequent months, the patient exhibited low-grade fever, dyspnea, and progressive desaturation, leading to respiratory failure necessitating home oxygen therapy. A PCR test confirmed SARS-CoV-2 infection, prompting suspicion of persistent COVID-19. Imaging and biopsy results were consistent with cryptogenic organizing pneumonia (COP), but the patient showed no response to treatment, including corticosteroids and immunosuppressants. Remdesivir treatment yielded partial improvement but failed to achieve full resolution. Plitidepsin (2.5 mg/day for 3 days) under compassionate use led to negative PCR tests and normal respiratory function restoration within 3 days after treatment. SARS-CoV-2's impact on immunocompromised patients is concerning due to unique clinical features, challenges in viral clearance and immunization, and varied responses to approved treatments. A phase II clinical trial is underway to assess plitidepsin's efficacy in immunocompromised COVID-19 adults requiring hospital care.
adverse event (AE); computed tomography (CT); coronavirus disease 2019 (COVID-19); C-reactive protein (CRP); cryptogenic organizing pneumonia (COP); diffusing capacity of the lungs for carbon monoxide (DLCO); eukaryotic elongation factor 1A (eEF1A); half maximal inhibitory concentration (IC50); immunoglobulin G (IgG); left upper lobe (LUL); liters per minute (LPM); mucosa-associated lymphoid tissue (MALT); polymerase chain reaction (PCR); right upper lobe (RUL); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Hematological cancer patients face an elevated risk of clinical severity, and mortality upon contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1-3]. Furthermore, hematological cancer patients exhibit prolonged viral shedding, sustained immune dysregulation, and diminished seroconversion compared to those with solid cancers [2,4].
The use of immunotherapy has also been linked to more severe outcomes and a higher cytokine storm risk [5,6]. Therefore, potent antivirals capable of clearing the viral infection are essential for managing hematological cancer patients [6]. Preclinical pharmacology studies demonstrate that plitidepsin, a marine-derived cyclic peptide targeting eukaryotic elongation factor 1A (eEF1A), is a potent inhibitor of SARS-CoV-2 growth in vitro, with half maximal inhibitory concentration (IC50) in the nanomolar range across different SARS-CoV-2 variants [7].
The safety and toxicological profile of three doses of plitidepsin (1.5, 2, and 2.5 mg/day for three days) were assessed in a multicenter, randomized clinical trial involving 46 hospitalized adult COVID-19 patients (APLICOV-PC, ClinicalTrials.gov Identifier: NCT04382066). Plitidepsin treatment was well-tolerated, with only two grade 3 treatment-related adverse events (AEs): hypersensitivity and diarrhea [8]. Plitidepsin's tolerability as a rescue treatment has also been demonstrated in 33 immunocompromised patients with persistent COVID-19 who were unsuitable for other antiviral treatments [9].
This case report provides a comprehensive clinical and evolutionary overview of an immunocompromised patient with persistent COVID-19, highlighting the treatment approach involving plitidepsin.
We present the case of a 55-year-old male with medical history of low-grade gastric mucosa-associated lymphoid tissue (MALT) B-cell lymphoma diagnosed in 2019 and treated with rituximab and bortezomib, achieving complete remission in 2020 and undergoing bimonthly rituximab maintenance treatment (last dose in June 2022). He was diagnosed with Waldenström macroglobulinemia, without a treatment indication.
In April 2022, mild SARS-CoV-2 infection was detected, which resolved spontaneously without hospitalization or further testing. In May 2022, the patient experienced intermittent low-grade fever and associated mild dyspnea, without additional symptoms. Due to suspected bacterial infection in the ear-nose-throat region, antibiotic treatment was initiated with no evident symptom resolution. In June 2022, persistent low-grade fever led to a medical consultation. A chest computed tomography (CT) scan revealed widespread bilateral lung infiltrates, particularly accentuated in both upper lobes and predominantly on the right side, consistent with cryptogenic organizing pneumonia (COP). Prednisone treatment at 60 mg/day was initiated [10]. After 10 days, fever and dyspnea subsided, and the prednisone dosage was reduced to 30 mg/day. Two days later, slightly elevated erythrocyte sedimentation rate and C-reactive protein (CRP) levels were observed without symptom recurrence, prompting further reduction to 20 mg/day.
In August 2022, the patient again presented with low-grade fever and exertion-induced dyspnea. Due to symptom recurrence upon prednisone dosage reduction, a repeat chest CT scan (August 2022) revealed worsening radiological findings, including significant infiltrates in the right upper lobe (RUL), patchy infiltrates bilaterally in mid and lower lung fields with peripheral and subpleural distribution, some showing air bronchograms, and one with a reversed halo sign in the anterior margin of the left upper lobe (LUL), still consistent with COP. Prednisone dosage was increased again to 60 mg, but the patient's clinical condition progressively worsened to dyspnea at minimal exertion. Another chest CT scan (October 2022) displayed worsening radiological results, including extensive infiltrates in the RUL, scattered infiltrates seen bilaterally in mid and lower lung fields with peripheral and subpleural distribution, some tending to alveolar coalescence, especially in RUL, and laminar atelectasis in the LUL, middle lobe, and lingula.
Despite high-dose corticosteroid treatment, clinical and radiological deterioration prompted a core needle biopsy in November 2022. Pathological findings indicated alveolar septal thickening with mild fibrosis and moderate chronic inflammation, consistent with COP within the context of corticosteroid treatment. An echocardiogram yielded no significant abnormalities, while a positron emission tomography-CT indicated the presence of inflammatory pathology. A bronchoscopy with cryobiopsy led to an organized pneumonia diagnosis. Following consultation with the Diffuse Interstitial Lung Disease Committee, mycophenolate mofetil (500 mg/12 h) was added to the ongoing 60 mg prednisone treatment [10]. Spirometry —diffusing capacity of the lungs for carbon monoxide (DLCO) 42%, forced expiratory volume in 1 second (FEV1) 68%, forced vital capacity (FVC) 73%— indicated a restrictive pattern with impaired diffusion. A 6-minute walk test revealed initial oxygen saturation of 87 percentage decreasing to 74%. Nocturnal home oxygen therapy was initiated due to baseline saturations around 75%.
On December 26th, 2022, the patient presented to the Emergency Department with worsening symptoms, including a basal saturation of 84%, tachypnea, and labored speech. Fine crackles up to bilateral mid-lung fields were observed upon examination, while the patient remained afebrile. Laboratory results indicated leukocytosis (13.17 x103/mm3) with neutrophilia (12.20x103/mm3), lymphopenia (0.46x103/mm3), and elevated CRP (3.95 mg/dL). Suspecting persistent SARS-CoV-2 infection, a nasopharyngeal PCR test was performed, yielding a positive result (CT Less than 30), while SARS-CoV-2 immunoglobulin G (IgG) serology testing was negative (Table 1). A repeat CT scan demonstrated a deterioration compared to previous scans (Figure 1).
Table 1: PCR results and dates.
Figure 1: High-resolution Computed Tomography (December 27th, 2022).
Given the active infection, mycophenolate was discontinued, and the patient received five-day course of remdesivir (December 26th-30th, 2022) followed by another five days of remdesivir along with a single sotrovimab infusion (January 2nd-7th, 2023) [11]. This treatment led to clinical improvement, with increased resting and exertion saturations and alleviation of low-grade fever. However, the need for 16-hour daily home oxygen therapy persisted, particularly during ambulation. Mindful of ongoing respiratory insufficiency —saturations at 93-94% with effort and nasal cannula at 3 liters per minute (LPM)—, a PCR test was repeated eight weeks post-treatment (March 8th, 2023), yielding a positive result (CT >30, see Table 1).
No lymphadenopathy or other significant findings are observed in the mediastinum or lung hilum, while there is extensive bilateral involvement in the lung parenchyma (red arrows). Predominant areas of ground-glass opacities, both centrally and peripherally located can be observed (blue arrows). Scattered alveolar infiltrates and linear images forming arches parallel to the pleural surface (yellow arrow). No pleural effusion is detected.
Considering the persistent positive PCR result and the lack of clinical improvement, compassionate use of plitidepsin was requested and administered for three days at a dose of 2.5 mg, along with appropriate premedication (March 8th-10th, 2023). A follow-up PCR on March 21st indicated a negative result, prompting a reevaluation (Table 1). The patient's basal oxygen saturations normalized without desaturation during exertion, leading to the discontinuation of home oxygen therapy. Plitidepsin was well tolerated with no AEs reported. Prednisone treatment was tapered off. A subsequent chest X-ray displayed no significant findings, and a control CT scan is scheduled for December 2023. Subsequently, the patient remained asymptomatic, free of oxygen therapy, with no new COVID-19 episodes, consistently testing negative by nasopharyngeal swab PCR (7 months follow-up). Regular check-ups for the underlying disease have been conducted without further complications.
Contributors to prolonged viral replication and inadequate clearance in patients with hematological neoplasms are inherent immune defects related to their primary disease and/or resulting from antitumoral therapies [12,13]. Additionally, subacute, or chronic COVID-19 pneumonia can lead to persistent lung damage and viral escape phenomena [14].
Suppression of viral replication in hematological cancer patients is crucial not only due to their elevated risk of complications but also to prevent de novo mutations resulting from persistent viral replication, coupled with the emergence of resistance to available antivirals [15].
There are currently no established clinical guidelines for managing persistent SARS-CoV-2 viral replication in rituximab-treated patients. Moreover, this patient population is underrepresented in COVID-19 clinical trials, resulting in varying treatments reported in the literature [16-22].
Despite the obvious limitation of describing only one patient, our case highlights the potential utility of plitidepsin as a promising antiviral therapy for immunocompromised patients with persistent SARS-CoV-2 infection, particularly those with hematological malignancies. Further research in larger cohorts and controlled clinical trials are essential to establish the efficacy, safety, and optimal usage of plitidepsin in this patient population. A phase II study assessing the efficacy of plitidepsin in immunocompromised COVID-19 adult patients requiring hospital care (NEREIDA, ClinicalTrials.gov Identifier: NCT05705167) is ongoing.
In patients with compromised immune systems, clinical manifestations of SARS-CoV-2 infection can mimic pulmonary interstitial diseases, with the virus persisting for months, sometimes despite antiviral treatments. In such cases, it is crucial to suspect and rule out the presence of SARS-CoV-2 in the respiratory tract and achieve viral clearance to prevent viral reactivations in high-risk patients. The compassionate use of plitidepsin in a high-risk patient with prolonged SARS-CoV-2 infection was well-tolerated and associated with PCR negativity, along with sustained symptomatic resolution. The development of new antivirals for COVID-19 in high-risk patients is imperative.
We thank the patient, and his relatives, for their generosity in allowing the publication of the patient’s data as a case report.
We obtained institutional written consent from the patient for publication of his data under anonymized format.
PL conceived the initial study concept, formulated the case report, conducted the diagnosis, oversaw patient care and ongoing monitoring, collected patient data, and played a pivotal role in both drafting and critically reviewing the article for its intellectual content.
CV; MH performed the diagnosis, management and regular follow-up of the patient.
RL; MPP analyzed patient data, undertook the writing and editing processes, and contributed scientific guidance along with a thorough review of the article's intellectual content.
XELE provided scientific, administrative, and logistic support.
ES gathered and analyzed patient data, conducted the writing and editing tasks and contributed scientific assistance, including a meticulous review of the article’s intellectual content.
The current manuscript has been reviewed and agreed upon by all authors.
ES and MPP are full-time employees of PharmaMar, S.A (Madrid, Spain).
XELE and RL are full-time employees and shareholders of PharmaMar, S.A (Madrid, Spain).
All remaining authors have declared no conflicts of interest.
This study has been funded by Pharmamar, SA (Madrid, Spain).
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
